Overview

A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

Status:
NOT_YET_RECRUITING

Trial end date:
2030-01-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to identify recommended Phase 3 doses (RP3D) for treatment combination (GR1803 injection plus anti-CD38 monoclonal antibody) and to characterize the efficacy of RP3D for the treatment combination.

Phase:

PHASE1

Details

Lead Sponsor:

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Treatments:

daratumumab